# The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

> **NCT05202275** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 43 (estimated)

## Conditions studied

- Nausea
- Vomiting
- Head and Neck Squamous Cell Carcinoma
- Radiotherapy Side Effect

## Interventions

- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT05202275
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2022-12
- **Final completion:** 2023-09
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2022-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05202275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05202275, "The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05202275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*